ROS1 and neoplasm: Since the amino acid sequence of the kinase domains of ROS1 and ALK are highly homologous, selective inhibitors of ALK, including crizotinib, have shown anti-tumor activity in vitro and have been explored clinically in the treatment of patients with ROS1-rearranged tumors [5–13].